This article is more than 5 years old. Information may no longer be current.

Lumigan receives positive recommendation from EU

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Lumigan is one step closer to European regulatory approval. Yesterday Europe's Committee for Proprietary Medicinal Products recommended the glaucoma drug be approved for marketing by the European Commission.

Lumigan (bimatoprost ophthalmic solution, 0.03%) is Allergan's newest anti-glaucoma medication. Company spokesmen say they expect European approval in about 3 months.

Lumigan belongs to a class of IOP-lowering drugs called prostamides. Early clinical findings have determined Lumigan 0.003% once daily is more efficacious than other dosage concentrations of the medication (for more on the comparative study, see the Dec. 1 issue of Ocular Surgery News).

Lumigan received U.S. regulatory approval on March 16, 2001. It has also received approval in six Latin American countries. As of September 2001, year-to-date sales for Lumigan were $20.3 million.